This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Tagawa, S. T. et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J. Clin. Oncol. https://doi.org/10.1200/JCO.20.03489 (2021)
Related article
Heath, E. I. & Rosenberg, J. E. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat. Rev. Urol. 18, 93–103 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. ADC sacituzumab govitecan shows efficacy and safety. Nat Rev Urol 18, 384 (2021). https://doi.org/10.1038/s41585-021-00479-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-021-00479-9